Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review

Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review

Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review

Summary

Endo Pharmaceuticals Holding Inc. (Endo) is a pharmaceutical company focused on the research, development and commercialization of branded and generic prescription pharmaceuticals to treat pain principally in the US. Its banded product portfolio includes Frova, Lidoderm, Opana, Opana Er, Percocet, Percodan, Voltaren Gel, Moban, Endocet, Endodan, Morphine Sulfate and Zydone. The company is headquartered in Pennysylvania, United States.

Global Markets Direct’s Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of Endo Pharmaceuticals Holdings Inc.. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.

Scope

- Provides key company information for business intelligence needs.
- The company’s strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
- The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
- The report contains critical company information – business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
- The report provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
- Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Reasons to buy

- A quick “one-stop-shop” to understand the company.
- Enhance business/sales activities by understanding customers’ businesses better.
- Get detailed information and financial and strategic analysis on companies operating in your industry.
- Identify prospective partners and suppliers – with key data on their businesses and locations.
- Capitalize on competitor's weaknesses and target the market opportunities available to them.
- Compare your company’s financial trends with those of your peers / competitors.
- Scout for potential acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

Table Of Contents

Table Of Contents 2
List of Tables 3
List of Figures 3
Key Facts 4
Business Description 4
Major Products and Services 5
History 6
SWOT Analysis 8
SWOT Analysis - Overview 8
Endo Pharmaceuticals Holdings Inc. - Strengths 8
Endo Pharmaceuticals Holdings Inc. - Strengths - Strong Financial Performance 8
Endo Pharmaceuticals Holdings Inc. - Strengths - Increasing Sales of Branded Products 8
Endo Pharmaceuticals Holdings Inc. - Strengths - Sturdy Research and Development Activities 8
Endo Pharmaceuticals Holdings Inc. - Weaknesses 8
Endo Pharmaceuticals Holdings Inc. - Weaknesses - Increasing Reliance on Lidoderm 8
Endo Pharmaceuticals Holdings Inc. - Weaknesses - Dependence on Third Party Manufacturers 8
Endo Pharmaceuticals Holdings Inc. - Opportunities 8
Endo Pharmaceuticals Holdings Inc. - Opportunities - License and Collaboration Agreements 8
Endo Pharmaceuticals Holdings Inc. - Opportunities - Pipeline Products 9
Endo Pharmaceuticals Holdings Inc. - Opportunities - Changing Demographics 9
Endo Pharmaceuticals Holdings Inc. - Opportunities - Medicare Part D 9
Endo Pharmaceuticals Holdings Inc. - Threats 9
Endo Pharmaceuticals Holdings Inc. - Threats - Product Liability 9
Endo Pharmaceuticals Holdings Inc. - Threats - Changing Political Climate in the US 9
Endo Pharmaceuticals Holdings Inc. - Threats - Tightening of the FDA’s Regulatory Oversight 9
Endo Pharmaceuticals Holdings Inc. - Threats - Emergence of Biogenerics / Biosimilars 9
Key Competitors 11
Key Employees 11
Key Employee Biographies 12
Company Statement 13
Locations And Subsidiaries 15
Locations And Subsidiaries - Head Office 15
Locations And Subsidiaries - Other Locations & Subsidiaries 15
Financial Ratios 16
Financial Ratios - Capital Market Ratios 16
Financial Ratios - Annual Ratios 16
Financial Ratios - Interim Ratios 17
Financial Ratios - Ratio Charts 18
Appendix 19
Methodology 19
Ratio Definitions 19
About Global Markets Direct 22
Contact Us 22
Disclaimer 22


List of Tables

Endo Pharmaceuticals Holdings Inc., Key Facts 4
Major Products and Services 5
Endo Pharmaceuticals Holdings Inc., History 6
Endo Pharmaceuticals Holdings Inc., Key Employees 11
Endo Pharmaceuticals Holdings Inc., Key Employee Biographies 12
Endo Pharmaceuticals Holdings Inc., Subsidiaries 15
Endo Pharmaceuticals Holdings Inc., Ratios based on current share price 16
Endo Pharmaceuticals Holdings Inc., Annual Ratios 16
Endo Pharmaceuticals Holdings Inc., Interim Ratios 17
Currency Codes 19
Capital Market Ratios 19
Equity Ratios 20
Profitability Ratios 20
Cost Ratios 20
Liquidity Ratios 21
Leverage Ratios 21
Efficiency Ratios 21


List of Figures

Endo Pharmaceuticals Holdings Inc., Ratio Charts 18